Share
1,206 Posts.
lightbulb Created with Sketch. 116
clock Created with Sketch. 28/08/15
08:22
Share
Originally posted by oody1
↑
IMO Invion has massive potential. A market cap of $14M and 3 drugs with potential billion dollar sales just doesn't make sense to me. However the market is punishing Invion for the time taken to develop these drugs and its rather low cash position. This is going to be a long-term play. Positive phase 2 trials for smoking cessation and a partner/sale for Cpn10 and the market should react positively. Mesoblast has a market cap of 1B and has a number of its drugs in phase 3 trials. Invion has a better chance of achieving success as there seems to be strong evidence on repurposing nadolol for asthma/smoking cessation and inhaled zafirlukast has already been shown to be effective when administered in the lung. Accumulate now IMO and let Dr Glass and his team achieve the success we know they can.
Expand
Interested to hear our Chairman Brett Heading is leaving McCulloch Robinson Lawyers after 36 years. Wish him well.
(20min delay)